We included seven randomised trials with 296 participants. Four trials examined nifedipine and the remainder nicardipine. Comparisons were with placebo in six trials and with both dazoxiben and placebo in one trial (only the nifedipine versus placebo data were used within this review ). Treatment with oral calcium channel blockers was minimally effective in primary Raynaud's phenomenon at decreasing the frequency of attacks (standardised mean difference of ; 95% confidence interval ( CI ) to , P = ). This translates to (95% CI to ) fewer attacks per week on calcium channel blockers compared to placebo . One trial provided details on duration of attacks reporting no statistically significant difference between the nicardipine and placebo groups (no P value reported). Only two trials provided any detail of statistical comparisons of (unvalidated) severity scores between treatment groups: one of these trials (60 participants) reported a mean severity score of on placebo and on nicardipine, difference (95% CI of difference 0 to , no P value reported) and the other trial (three participants only with primary Raynaud's phenomenon) reported a median severity score of 2 on both nicardipine and placebo treatment ( P > ) suggesting little effect on severity. Participant-preference scores were included in four trials, but in only two were results specific to participants with primary Raynaud's phenomenon, and scoring systems differed between trials: scores differed between treatments in only one trial , in which 33% of participants on placebo and 73% on nifedipine reported improvement in symptoms ( P < ). Physiological measurements were included as outcome measures in five trials (different methodologies were used in each): none of these trials found any statistically significant between-treatment group differences. Treatment with calcium channel blockers appeared to be associated with a number of adverse reactions, including headaches, flushing and oedema (swelling). Overall, the trials were classed as being at low or unclear risk of bias ; and the quality of the evidence presented was moderate for number of attacks, very low for duration of attacks, high for severity scores and low for patient preference scores.
Stanozolol is the generic name of stanozolol in English , German , French , and Japanese and its INN , USAN , USP , BAN , DCF , and JAN , while stanozololum is its name in Latin , stanozololo is its name in Italian and its DCIT , and estanozolol is its name in Spanish .    Androstanazole , stanazol , stanazolol , and estanazolol are unofficial synonyms of stanozolol.   The drug is also known generically by its former developmental code names NSC-43193 and WIN-14833 .